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Abstract: Exercise in humans and animals increases plasma bilirubin levels, but the mechanism
by which this occurs is unknown. In the present study, we utilized rats genetically selected for
high capacity running (HCR) and low capacity running (LCR) to determine pathways in the liver
that aerobic exercise modifies to control plasma bilirubin. The HCR rats, compared to the LCR,
exhibited significantly higher levels of plasma bilirubin and the hepatic enzyme that produces it,
biliverdin reductase-A (BVRA). The HCR also had reduced expression of the glucuronyl hepatic
enzyme UGT1A1, which lowers plasma bilirubin. Recently, bilirubin has been shown to activate the
peroxisome proliferator-activated receptor-α (PPARα), a ligand-induced transcription factor, and the
higher bilirubin HCR rats had significantly increased PPARα-target genes Fgf21, Abcd3, and Gys2.
These are known to promote liver function and glycogen storage, which we found by Periodic
acid–Schiff (PAS) staining that hepatic glycogen content was higher in the HCR versus the LCR. Our
results demonstrate that exercise stimulates pathways that raise plasma bilirubin through alterations
in hepatic enzymes involved in bilirubin synthesis and metabolism, improving liver function, and
glycogen content. These mechanisms may explain the beneficial effects of exercise on plasma bilirubin
levels and health in humans.
Keywords: bilirubin; BVRA; exercise; obesity; PPARalpha; glycogen; mitochondria; heme oxygenase;
HO-1; HO-2
1. Introduction
Genetics or a sedentary lifestyle may lead to obesity and other deleterious comorbidities that can
reduce life expectancy. Exercise and diet modifications are beneficial in reducing body weight and
adverse outcomes. Recent investigations have shown that bilirubin, which was typically considered a
toxic bile substance, has beneficial actions on regulating body weight [1,2]. Indeed, there has been a
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correlation showing that plasma bilirubin levels are lower in obese humans [3–5]. The enzyme that
produces bilirubin, BVRA [6,7], is also reduced in obese humans compared to lean matched controls [8].
Studies indicate that bilirubin levels might increase with exercise [9,10] and fasting [11–14], implying a
possible role for metabolic regulation.
There are multiple ways of possibly regulating plasma bilirubin, which is a product of the heme
oxygenase (HO) pathway [15]. Heme from lysed red blood cells is broken down to biliverdin by
HO (HO-1 or HO-2), and this is further catabolized by biliverdin reductase (BVR) to unconjugated
bilirubin [16]. This version of bilirubin is insoluble and requires glucuronidation by the UGT1A1
enzyme for solubility [17], and then it is deposited in the bile, and eventually, the intestine, ultimately
reducing plasma levels [16]. Hence, regulation of HO, BVR, or UGT1A1 can all serve as mechanisms to
regulate plasma bilirubin levels and possibly body weight. However, how these enzymes function
during exercise to modify bilirubin levels is unknown.
We have shown that bilirubin has a hormonal function by binding directly to the fat-burning nuclear
receptor PPARα inducing transcriptional activity and gene regulation [18–20]. PPARα is induced by
fasting [21], which is also when bilirubin is the highest [11–14]. There may be a bilirubin-induced
endocrine function during fasting, which has been shown for PPARα-mediated induction of fibroblast
growth factor 21 (FGF21) [22]. We have previously demonstrated that bilirubin-PPARα increased
FGF21 levels, activating mitochondrial function and β-oxidation for utilization of fats for energy
reducing body weight [18,19,23–25]. The function of bilirubin-PPARα in exercise has not been explored.
While most studies have focused on HO-1 expression and bilirubin as an end product, in this study,
we analyzed each enzyme in the HO pathway in rats genetically selected for high and low aerobic
exercise capacity. We found that the BVRA is enhanced in the high capacity running (HCR) compared
to the low capacity running (LCR) rats. Also, we found that UGT1A1 expression was reduced, and
together these caused higher plasma bilirubin levels and PPARα-induced hepatic β-oxidation pathway.
Together, these posit that bilirubin may function to enhance exercise and aerobic capacity, and this
may help reduce body fat. Increasing serum bilirubin by targeting the HO-BVR-UGT1A1 pathway,
which are enzymes that regulate its production or turnover, might be a useful therapeutic approach for
exercise performance or obesity.
2. Materials and Methods
2.1. Animals
Studies were performed on male rats 59–63 weeks of age from generation 41 of HCR/LCR rat model,
which was developed by two-way selective breeding in genetically heterogeneous rats for intrinsic
exercise capacity as previously described [26–29]. In short, rats were phenotyped at 11 weeks of age
using a speed-ramped maximal treadmill running test, and we devised to pattern clinical stress tests.
The experimental procedures and protocols of this study were approved by the Institutional Animal
Care and Use Committee of the University of Toledo Health Science Center and conformed to the
National Institutes of Health Guide for the Care and Use of Laboratory Animals. Rats were maintained
on standard laboratory diet (Laboratory Rodent Diet 5001; LabDiet, Richmond, IN, USA) with free
access to water throughout the study. The running protocol consisted of two days of re-education to
treadmill walking for no more than 5 min, followed by a single test of maximal treadmill running
distance carried on day 3. The treadmill (model Exer-4, Columbus Instruments, Columbus, OH, USA)
was set at a constant grade of 15◦ and an initial speed of 10 m/min. Speed was progressively ramped
1 m/min every 2 min until the rat could no longer keep pace and continue running. Total run time
and body weight were recorded. The distance run in meters (m) was calculated from treadmill speed
(m/min). The next day, rats were fasted overnight prior to the terminal collection of blood and tissue
samples in rats deeply anesthetized with isoflurane induction.
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2.2. Liver Histology
To determine hepatic differences of the HCR and LCR rats, livers were mounted and frozen in
Tissue-Tek O.C.T and sectioned at 10 µm. Hematoxylin and Eosin (H&E) and Periodic acid–Schiff
(PAS) staining were performed as previously described [23,24,30]. Frozen sections were air-dried and
fixed in 10% neutral buffered formalin. Sections were briefly rinsed in tap water followed by 60%
isopropanol and stained for 15 min in the Oil Red O solution. Sections were further rinsed in 60%
isopropanol and nuclei stained with hematoxylin followed by aqueous mounting and coverslipping.
Slides were imaged at 20×magnification using a color video camera attached to an Olympus VS120
slide scanning microscope (Olympus Corporation, Center Valley, PA, USA). Images were analyzed
using the Olympus OlyVIA software. Image J (NIH) was used to quantitate the glycogen content. Data
are presented as the + SEM for each group.
2.3. Quantification of Small Molecules in Plasma
Were measured as we previously described [30]. In brief, following an overnight fast, blood
samples were obtained via the abdominal aorta under isoflurane anesthesia for plasma lipids and
metabolites. Nuclear magnetic resonance (NMR) spectroscopy experiments were acquired using a
14.0 T Bruker magnet equipped with a Bruker AV-III console operating at 600.13 MHz. (Bruker Scientific
LLC, Billerica, MA, USA). All spectra were acquired in 3 mm NMR tubes using a Bruker 5 mm QCI
cryogenically cooled NMR probe. Plasma samples were prepared and analyzed according to the Bruker
In-Vitro Diagnostics research (IVDr) protocol. Sample preparation consisted of combining 50 µL of
plasma with 150 µL of the buffer supplied by Bruker Biospin specifically for the IVDr protocol. For
1D 1H NMR, data was acquired using the 1D-NOE experiment, which filters NMR signals associated
with broad line widths arising from proteins that might be present in plasma samples that adversely
affect spectral quality. Experiment conditions included: Sample temperature of 310K, 96k data points,
20 ppm sweep width, a recycle delay of 4 s, a mixing time of 150 ms, and 32 scans. The analysis was
performed using a regression analysis of the NMR data, which is done automatically as part of the
IVDr platform, as previously described [31].
2.4. Quantitative Real-Time PCR Analysis
Total RNA was harvested from HCR and LCR rats by lysing livers using a Qiagen Tissue
Lyser LT (Qiagen Inc, Germantown, MD, USA) and then extraction by 5-Prime PerfectPure
RNA Tissue Kit (Fisher Scientific Company, LLC). Total RNA was read on a NanoDrop 2000
spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA), and cDNA was synthesized
using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). PCR amplification
of the cDNA was performed by quantitative real-time PCR using TrueAmp SYBR Green qPCR
SuperMix (Alkali Scientific, Fort Lauderdale, FL, USA) for gene-specific primers as previously
described [18,23,24,32]. The thermocycling protocol consisted of 5 min at 95 ◦C, 40 cycles of 15 s at
95 ◦C, and 30 s at 60 ◦C, finished with a melting curve ranging from 60–95 ◦C to allow distinction of
specific products. Normalization was performed in separate reactions with primers to GAPDH.
2.5. Bilirubin Measurements
Total bilirubin was measured using a Vet Axcel serum chemistry analyzer (AlfaWassermann,
West Caldwell, NJ, USA) from 30 µL of plasma. Samples were measured in duplicate with standards
supplied by the manufacturer, as previously described [20]. Data are presented as mg/dL.
2.6. Statistics
All data are presented as mean + S.E.M. Differences between treatment groups were determined
using the student t-test. A p < 0.05 was considered to be significant. All analyses were performed with
GraphPad Prism 8 software (GraphPad Software, Inc., San Diego, CA, USA).
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3. Results
The HCR and LCR total running distance were measured, and as expected [33] the HCR rats had
significantly (p < 0.0001) ran further and had higher time to exhaustion during running (Figure 1A,B).
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(D) Body Weight. (E) Age of rats. * p < 0.05 as compared to LCR rats. *** p < 0.01 as compared to LCR
rats. **** p < 0.001 as compared to LCR rats. n = 9/group.
Exercise capacity increases lactic acid in the blood [34,35], and this was also found to be significantly
(p < 0.05) higher in the HCR rats (Figure 1C). The higher aerobic exercise HCR rats had reduced body
weights compared to the LCR (Figure 1D). Age of the rats did not affect these outcomes, as there was
no difference in the ge of the rats (Figure 1E).
There was also no difference in liver or heart weights (Figure 2A,B). Histological H&E staining in
the HCR and LCR rats did not show any presence of lipid droplets (steatosis), fibrosi s, or inflammatory
foci. Overall, there were no noticeable differences in the hepatic visualization between the HCR and
LCR rats.
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Bilirubin has been shown to increase with exercise capacity in humans [9,10]. To determine
possible differential in hepatic function between the HCR and LCR rats, we measured plasma bilirubin
levels, which is a surrogate marker of liver function. We found that plasma bilirubin levels were
significantly (p < 0.05) higher in the HCR high aerobic running rats compared to the LCR (Figure 3A).
We measured the enzyme expression of the HO pathway to determine if they were altered with high
aerobic exercise capacity HCR rats. We found no differences between the HCR and LCR rats for the
HO isoforms, Hmox1 (HO-1), or Hmox2 (HO-2) (Figure 3B,C). However, the enzyme that generates
bilirubin, BVRA (Blvra gene), was significantly (p < 0.01) higher in the HCR rats. The enzyme that
reduces plasma bilirubin levels, UGT1A1 (Ugt1a1 gene), was significantly (p < 0.05) reduced in the
HCR. These results show that higher aerobic exercise capacity enhanced BVRA and reduced UGT1A1
to elevate bilirubin levels.
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We have shown that bilirubin-PPARα activates glycogen storage in the liver of obese mice [24].
Here, we observed that the HCR rats had significantly (p < 0.01) higher glycogen levels compared to
the LCR (Figure 5A,B). The PPARα-target gene Gys2 (glycogen synthase-2) [30,37], was significantly
(p < 0.05) higher in the HCR rats, but not the glucose and fat scavenger Cd36 (Figure 5C,D).
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We have shown that bilirubin activation of PPARα induces mitochondrial function [20], and that
mice with the loss of BVRA have reduced mitochondrial function [38]. Therefore, we measured
citric acid and acetic acid in the HCR and LCR rats, two metabolites associated with mitochondrial
activity [39–41]. The HCR rats had significantly increased levels of citric acid and acetic acid
(Figure 6A,B).
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4. Discussion
Physical exercise provides multiple benefits to the body, and a sedentary lifestyle and weight
gain are associated with an increased risk of obesity, cardiovascular, and metabolic diseases [42,43].
Previous studies have found that exercise increases serum bilirubin levels [9,10]. In the past, bilirubin
has been negatively viewed as a toxic bile substance and a biomarker for liver dysfunction. This was
mostly reflected from the severe hyperbilirubinemia observed in the extremely rare Crigler–Najjar
syndrome with levels in the 400–700 µM range, which can cause brain damage in infants [44]. The
past two decades of heme oxygenase and bilirubin research has shown that bilirubin has many
health benefits [1,2,45]. For instance, humans with the UGT1A1*28 Gilbert’s polymorphism that
causes reduced levels of the UGT1A1 enzyme and increased plasma bilirubin levels in the 18–50 µM
range [46,47], have been shown to have decreased incidence of cardiovascular disease [48,49]. People
exhibiting mildly elevated bilirubin levels (>12 µM) were shown to have significantly fewer metabolic
disorders such as fatty liver disease, obesity, or type II diabetes [5,50–56]. These studies have opened a
new perspective for bilirubin and that there are health benefits with mild hyperbilirubinemia.
The results of the present study showed that aerobic exercise increases hepatic BVRA expression
while at the same time, suppressing UGT1A1. BVRA is the rate-limiting enzyme in the formation of
bilirubin. UGT1A1 is the enzyme in the liver responsible for the conjugation of bilirubin so that it can
be eliminated in the bile. Genetically deficient mice and animals treated with UGT1A1 antagonist
or antisense oligonucleotides exhibit an increase in serum bilirubin levels according to the degree
of UGT1A1 inhibition [23,57,58]. We have previously shown that mice with the human UGT1A1*28
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Gilbert’s polymorphism and hyperbilirubinemia on a high-fat diet had significantly reduced hepatic
fat accumulation and increased liver glycogen content compared to controls [23]. These indicate that
mildly elevating plasma bilirubin levels have beneficial effects on liver pathology. While past studies
have demonstrated the relationship between exercise and serum bilirubin levels, this is the first study
to identify a potential mechanism by which exercise regulates serum bilirubin levels. HCR rats are a
genetic model of high aerobic capacity similar to highly conditioned human athletes. Interestingly,
a study of participants in a 1600 km ultramarathon run, which occurred over 16 days, found elevations
in serum bilirubin levels at the end of the run [59]. This study did not measure the factors controlling
the higher bilirubin levels. However, our results show that aerobic exercise induces hepatic BVRA and
suppresses UGT1A1 to elevate plasma bilirubin.
Understanding the potential physiological benefit of increased bilirubin released during exercise
is necessary to uncovering bilirubin’s diverse metabolic functions. One study showed in humans
that increased aerobic exercise is correlated with higher levels of total bilirubin [9]. Another study
demonstrated that athletes, or those who regularly exercise, have a greater baseline bilirubin level of
approximately 29 µM compared to non-athletes [10]. Unfortunately, there are not many studies that
delve into the clinical outcome of elevated bilirubin during exercise.
It is possible that bilirubin protects muscle fibers from injury induced by exercise, delays the
development of fatigue, and promotes recovery by inhibiting the disturbance of mitochondrial
function [20,60]. While the effect of bilirubin on muscle tissue fibers is currently not known, we have
previously shown that the UGT1A1*28 Gilbert’s polymorphism mice on a high-fat diet had greater
lean body mass compared to high-fat-fed controls [23]. We also showed that treating obese mice with
bilirubin nanoparticles increased lean body mass and mitochondrial function in white adipose tissue
(WAT) [20]. Bilirubin may positively affect muscle tissue to increase lean body mass, or may also target
adipose to reduce fat, or might benefit both to improve metabolic outcomes. Noland et al. showed
that HCR rats had enhanced mitochondrial activity in muscle compared to the LCR [36]. Our results
here indicate that the liver control of bilirubin may be a factor. However, both adipose or muscle
tissues may be contributing to the mitochondrial function and higher plasma acetic and citric acid
levels. Low intrinsic running capacity is associated with reduced skeletal muscle substrate oxidation
and lower mitochondrial content in white skeletal muscle [61]. Adipose-specific BVRA knockout mice
fed a high-fat diet exhibited increased fat mass and significantly fewer mitochondria in WAT than
floxed control fed the same diet [38]. A liver to muscle or liver to adipose circuit may exist via BVRA
mediated production of bilirubin, enhancing aerobic exercise capacity due to the mitochondrial effects
of bilirubin [19,20,38,62], which might contribute to the high aerobic capacity of the HCR rats. Future
studies should determine the metabolic actions of bilirubin and BVRA in WAT and adipose depots of
the HCR and LCR.
We have recently shown that bilirubin has a hormonal function by binding directly to PPARα,
inducing transcriptional activity of genes involved in hepatic glycogen synthesis and β-oxidation in
models of dietary-induced non-alcoholic fatty liver disease (NAFLD) [18–20]. In the present study,
we did not find a change in PPARα mRNA expression in the livers of the HCR compared to the LCR rats.
This finding agrees with others who have also found that PPARα levels did not change with exercise in
rats [28]. The interesting conundrum is that the PPARα transcriptional activity, but not expression,
is higher during exercise [63,64]. The reason for the enhanced PPARα transcriptional activity could
be due to PPARα ligands such as free fatty acids that are released from adipose tissue (lipolysis) [65]
or increased bilirubin levels, both of which drive PPARα transcriptional activity. There has been a
correlation for palmitoylethanolamide (PEA) and oleoylethanolamine (OEA), which are natural PPARα
ligands derived from fatty acids, and their activation of PPARα may regulate bilirubin levels [66].
Others have proposed that PPARα may regulate bilirubin homeostasis [67]. These observations suggest
a possible feedback loop for bilirubin-PPARα, which might be a fundamental circuit for exercise.
PPARα is known to increase glycogen content in the liver. Nolan et al. found no difference in
glycogen synthesis in muscle tissue between the HCR and LCR rats [36]. However, we show here for
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the first time that glycogen was significantly higher in the livers of the HCR rats compared to the LCR.
The increased glycogen stores in the livers of the HCR rats are most likely due to bilirubin-PPARα
induction of glycogen synthase-2 (Gys2) [24]. There are hepatic pathways that are mediated by bilirubin
that increases glycogen storage [15,68]. In muscle, the predominant isoform is Gys1, which is not
known to be PPARα-regulated. It could be the reason for the lack of differences in muscle glycogen
synthesis between HCR and LCR rats. The likely contributor to the higher hepatic glycogen content
in the HCR rats is enhanced bilirubin-PPARα-GYS2. We have previously shown that mice with a
hepatocyte-specific knockout of BVRA and reduced hepatic bilirubin had significantly lower glycogen
content and suppressed PPARα activity [24]. We also demonstrated in the Gilbert’s (UGTA1A*28)
mice with hyperbilirubinemia that they had significantly higher hepatic glycogen content on a high-fat
diet compared to obese controls [23]. There may be a bilirubin-PPARα axis that is essential to regulate
glycogen storage, and this is beneficial during exercise increasing aerobic capacity.
5. Conclusions
The present study demonstrates that rats genetically selected for high aerobic capacity exhibit
increased plasma bilirubin levels due to alterations in key hepatic enzymes responsible for bilirubin
generation or metabolism. These studies show that the mechanistic actions that regulate plasma
bilirubin levels during exercise might be beneficial medically. Activating BVRA or inhibition of
UGT1A1 may serve as therapeutics for improving exercise performance or weight management.
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